Lantern Pharma (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, has received regulatory and Institutional Review Board approvals in Taiwan to open Part 2 of its Phase 2 HARMONIC trial of LP-300. The lead Taiwan site is now open to accrual and actively screening patients, with the company anticipating IRB approval at two additional sites during the fourth quarter. In the United States, a central IRB has approved the amended protocol, and clinical sites have begun identifying patients with the EGFR exon 21 L858R mutation. This expansion is significant because it could accelerate enrollment and bring LP-300 closer to addressing a critical unmet need in non-small cell lung cancer.
Part 2 of the HARMONIC trial will enroll patients with the L858R mutation who have progressed after tyrosine kinase inhibitor treatment. The amended protocol allows LP-300 to be administered for up to eight cycles in combination with carboplatin and pemetrexed, up from six cycles previously. Preliminary data showed median progression-free survival of 8.9 months among nine L858R patients who completed six cycles, compared with 8.3 months among all 16 L858R patients evaluated. While the company cautions that these findings are preliminary, exploratory, and based on small patient numbers, the extension to eight cycles could potentially deepen responses and improve outcomes. For investors and patients, this regulatory green light in Taiwan, a key Asian market with high lung cancer incidence, underscores Lantern's strategic push to globalize its clinical development.
The HARMONIC trial is powered by Lantern's proprietary RADR artificial intelligence and machine-learning platform, which integrates large-scale genomic and biological data to identify patients most likely to benefit from its therapies. This biomarker-driven approach is central to the company's mission to transform the cost, pace, and precision of oncology drug development. By targeting the L858R mutation, Lantern is focusing on a patient subgroup that often develops resistance to standard treatments, highlighting the potential of LP-300 to fill a therapeutic gap. The Taiwan approvals not only validate the trial's design but also provide access to a diverse patient population that could yield valuable data for regulatory submissions.
Lantern's pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI. The latest news and updates relating to LTRN are available in the company's newsroom at https://ibn.fm/LTRN. For a full view of the press release, visit https://ibn.fm/CqeDR.
BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences, is one of 75+ brands within the Dynamic Brand Portfolio at IBN. The platform delivers access to a vast network of wire solutions via InvestorWire to efficiently reach target markets, along with article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, and social media distribution. For more information, visit https://www.BioMedWire.com.
